GoodRx (NASDAQ:GDRX – Get Free Report) had its target price lowered by stock analysts at JPMorgan Chase & Co. from $7.00 to $6.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target would indicate a potential upside of 14.50% from the company’s current price.
GDRX has been the topic of a number of other reports. Truist Financial lowered their price objective on GoodRx from $8.00 to $5.50 and set a “hold” rating on the stock in a research report on Friday, November 10th. The Goldman Sachs Group lowered their price target on shares of GoodRx from $7.00 to $6.00 and set a “neutral” rating on the stock in a report on Friday, November 10th. Citigroup raised their price objective on shares of GoodRx from $7.00 to $11.00 and gave the stock a “buy” rating in a report on Thursday, August 10th. Morgan Stanley lowered their target price on shares of GoodRx from $8.00 to $5.50 and set an “equal weight” rating on the stock in a research note on Friday, November 10th. Finally, Credit Suisse Group increased their price target on shares of GoodRx from $7.00 to $8.00 and gave the stock a “neutral” rating in a research report on Thursday, August 10th. Nine equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $7.97.
GoodRx Stock Performance
GoodRx (NASDAQ:GDRX – Get Free Report) last announced its quarterly earnings data on Thursday, November 9th. The company reported $0.06 EPS for the quarter, meeting analysts’ consensus estimates of $0.06. GoodRx had a net margin of 2.04% and a return on equity of 2.25%. The business had revenue of $180.00 million during the quarter, compared to analyst estimates of $188.52 million. During the same quarter in the prior year, the business earned $0.07 earnings per share. The firm’s revenue for the quarter was down 3.9% on a year-over-year basis. On average, analysts forecast that GoodRx will post 0.08 EPS for the current year.
Institutional Investors Weigh In On GoodRx
Large investors have recently bought and sold shares of the business. Tudor Investment Corp Et Al acquired a new position in GoodRx in the third quarter worth $171,000. GSA Capital Partners LLP increased its stake in shares of GoodRx by 126.3% in the third quarter. GSA Capital Partners LLP now owns 116,658 shares of the company’s stock valued at $657,000 after buying an additional 65,099 shares in the last quarter. Rip Road Capital Partners LP raised its holdings in shares of GoodRx by 45.1% in the third quarter. Rip Road Capital Partners LP now owns 1,401,983 shares of the company’s stock valued at $7,893,000 after buying an additional 435,883 shares during the last quarter. Sectoral Asset Management Inc. acquired a new position in GoodRx during the 3rd quarter worth about $5,669,000. Finally, Legal & General Group Plc grew its holdings in GoodRx by 26.6% during the 3rd quarter. Legal & General Group Plc now owns 60,953 shares of the company’s stock worth $343,000 after acquiring an additional 12,823 shares during the last quarter. 33.63% of the stock is currently owned by institutional investors.
GoodRx Company Profile
GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.
- Five stocks we like better than GoodRx
- How to Calculate Return on Investment (ROI)
- 3 ETFs that offer extreme diversification
- 3 Healthcare Dividend Stocks to Buy
- Williams-Sonoma is a steal for buy-and-hold investors
- Dividend Payout Ratio Calculator
- A closer look at Warren Buffett’s latest surprise purchase
Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.